CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Changes Stockholders' Deficit

Consolidated Statements of Changes Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands	Preferred Stock Series C Convertible Preferred Stock	Preferred Stock	Common Stock Series C Convertible Preferred Stock	Common Stock Private Equity Offering	Common Stock	Treasury Stock	Additional Paid-in Capital Series C Convertible Preferred Stock	Additional Paid-in Capital Private Equity Offering	Additional Paid-in Capital	Accumulated Deficit	Private Equity Offering	Total
Beginning balance at May. 31, 2022					$ 720				$ 671,013	$ (766,131)		$ (94,398)
Beginning balance (shares) at May. 31, 2022		35			720,028	443
Stock issued for compensation					$ 1				344			345
Stock issued for compensation (in shares)					879
Stock issued for private offerings				$ 85				$ 17,459			$ 17,544
Stock issued for private offerings (in shares)				85,378
Issuance costs related to stock issued for private offerings									(6,289)			(6,289)
Conversion of preferred stock to common stock			$ 1				$ (1)
Conversion of preferred stock to common stock (in shares)	(1)		1,136
Warrant exercises					$ 1				263			264
Warrant exercises (in shares)					657
Deemed dividend paid in common stock due to down round provision, recorded in additional paid-in capital					$ 5				(5)
Deemed dividend paid in common stock due to down round provision recorded in additional paid-in capital (in shares)					4,620
Dividends accrued on Series C and D convertible preferred stock									(384)			(384)
Reclassification of warrants from liability to equity classified									8,601			8,601
Stock-based compensation									996			996
Reclassification of prior period preferred stock dividends									(4,265)	4,265
Net loss										(20,991)		(20,991)
Ending balance at Aug. 31, 2022					$ 813				687,732	(782,857)		(94,312)
Ending balance (shares) at Aug. 31, 2022		34			812,698	443
Beginning balance at May. 31, 2023					$ 919				731,270	(841,690)		(109,501)
Beginning balance (shares) at May. 31, 2023		34			919,053	443
Issuance of stock for convertible note repayment					$ 8				1,492			1,500
Issuance of stock for convertible note repayment (in shares)					8,661
Loss on induced conversion									2,004			2,004
Warrants issued in note offering									170			170
Stock issued for compensation					$ 1				154			155
Stock issued for compensation (in shares)					686
Warrant exercises					$ 3				297			300
Warrant exercises (in shares)					3,000
Dividends accrued on Series C and D convertible preferred stock									(373)			(373)
Reclassification of warrants from liability to equity classified									79			79
Stock-based compensation									348			348
Net loss										(11,571)		(11,571)
Ending balance at Aug. 31, 2023					$ 931				$ 735,441	$ (853,261)		$ (116,889)
Ending balance (shares) at Aug. 31, 2023		34			931,400	443